Table 2.
Novel FSGS partial proteinuria remission remained significantly associated with decreased likelihood of disease progression compared with those with no response after propensity score–stratified and propensity score–adjusted Cox proportional hazards analyses
| Proteinuria Assessment | Crude Data | Regression Results | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Complete Remission | Partial Remission | No Response | Unadjusted Model | Propensity Score Stratified (Quintiles) | Propensity Score Adjusted | ||||
| # of Events/# of Patients/(Risk per 100 Patient-Years) | # of Events/# of Patients (Risk per 100 Patient-Years) | # of Events/# of Patients (Risk per 100 Patient-Years) | HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value | |
| Novel | |||||||||
| Month 1 | 0/7 (0.0) | 17/69 (10.9) | 62/252 (12.0) | 0.8 (0.5 to 1.4) | 0.43 | 0.8 (0.4 to 1.4) | 0.36 | 0.7 (0.4 to 1.3) | 0.28 |
| Month 4 | 3/30 (4.2) | 17/94 (8.0) | 44/163 (13.0) | 0.5 (0.3 to 0.9) | 0.02 | 0.5 (0.3 to 0.9) | 0.01 | 0.5 (0.3 to 0.8) | 0.003 |
| Month 8 | 6/41 (6.6) | 13/71 (8.5) | 51/116 (20.1) | 0.4 (0.2 to 0.7) | <0.001 | 0.3 (0.1 to 0.5) | 0.002 | 0.3 (0.2 to 0.6) | 0.001 |
| Conventional | |||||||||
| Month 1 | 0/7 (0.0) | 22/88 (11.0) | 57/233 (12.2) | 0.6 (0.3 to 1.1) | 0.06 | 0.4 (0.1 to 1.7) | 0.21 | 0.5 (0.1 to 1.9) | 0.29 |
| Month 4 | 3/30 (4.2) | 24/114 (9.6) | 37/143 (12.4) | 0.8 (0.5 to 1.1) | 0.22 | 0.7 (0.4 to 1.3) | 0.23 | 0.7 (0.4 to 1.2) | 0.19 |
| Month 8 | 6/41 (6.6) | 19/85 (10.4) | 45/104 (20.0) | 0.4 (0.2 to 0.7) | 0.003 | 0.4 (0.2 to 0.8) | 0.01 | 0.4 (0.2 to 0.8) | 0.01 |
Propensity scores were calculated from the following covariates: baseline urine protein-to-creatinine ratio, baseline eGFR, exposure to steroid therapy, and exposure to calcineurin inhibitor therapy. Stratified results are from stratified Cox proportional hazards models where the baseline hazard is stratified by quintiles of propensity scores; adjusted results are from Cox proportional hazards models where the propensity score is included as a covariate. Adjusted analyses were also adjusted for study (National Institutes of Health-funded FSGS Clinical Trial, NephCure Accelerating Cures Institute, University of Michigan Nephrotic Syndrome Registry, or Clinical Phenotyping Resource and Biobank Core). 95% CI, 95% confidence interval; HR, hazard ratio.